Access to Quality Medicines and other Technologies Task Force

Meeting of the Asia Pacific Leaders Malaria Alliance March 12-13, 2014

Anshu Prakash


Ministry of Health and Family Welfare

Government of India

India: Profile

- 1210 million population (2011 census)
- 36 States/ UTs with average 32 Million population (range: 0.06 to 191 million)
- Malaria (2012)
 - API: 1.06/1000
 - Reported cases: 1.06 million
 - Pv cases 534129; Pf cases 524370
 - Reported deaths: 519

Shrinking – Malaria Map-India








Malaria in India (2001-2012)


Malaria in India




India reports about One million malaria cases annually

Source: NVBDCP

Decline in API and malaria deaths



Declining trend of malaria deaths in India



Antimalarial commodities

- Nation wide coverage
- Free of cost in public sector



Diagnosis of malaria


Microscopy

- At decentralised laboratories by trained technicians (~30000 labs in public sector)
- 95 million slides examined in 2012
- Results within 24 hours
- Cost to government (including operational cost): about 0.6 USD/test

P.falciparum P.vivax


RDT

- Introduced in 2004
- Monovalent (Pf only) RDTs till 2012
- Bivalent RDTs (Pf and Pv) since 2013
- Sensitivity >95% (Pf), >90% (Pv)
- Specificity >98%
- 14 million tests in 2012
- Cost to government (including operational cost): about 0.8 USD/test



Treatment of malaria: National Drug Policy

- All fever cases should preferably be investigated for malaria by microscopy or RDT
- P. falciparum
 - ACT first line antimalarial
 - Artesunate+SP all over India except NE states
 - Decision to introduce artemether lumefantrine in NE states
 - ACT also in 2nd and 3rd trimester of pregnancy and quinine in 1st trimester
 - Primaquine single dose as gametocytocidal
- P. vivax
 - Chloroquine 3 days + Primaquine for 14 days
 - Injectable artesunate/quinine for severe malaria
 - Centralized and decentralized procurement



QA of diagnostics/medicines

QA of microscopy

- Cross checking of all positive and 5% negative slides
- At state laboratories and Regional Offices for Health & FW


QA of RDTs

- Assess quality of RDTs procured and supplied by NVBDCP to various health facilities including ASHAs.
- Pre-dispatch QA and Post- dispatch QA to assess the quality of RDTs

QA of antimalarials

- CDSCO responsible for regulation of medicines
- QA/QC at the time of procurement

Monitoring antimalarial drug resistance



- Therapeutic efficacy studies at 15 sites each year
- 70 patients at each site enrolled
- Provide evidence to change drug policy
- Policies based on the results
- NIMR and NVBDCP

Integrated Vector Management

- Indoor Residual Spraying in selected high risk areas
 - DDT: 5000 metric tons/yr
 - Malathion: 10000 metric tons/yr
 - Synthetic pyrethroids: 1200 metric tons/yr
- Use of LLINs in areas with API>2
 - >12 million LLINs distributed by government
- Anti larval measures in urban areas
 - Larvicide e.g. temephos
 - Biological control e.g. Larvivorous fish,
 BTi
- Source reduction: Minor environmental engineering





NVBDCP: Review mechanisms

- National Vector Borne Disease Control Programme implemented all over india
- Regular monitoring by Government of India
- Independent monitoring and evaluation by Joint Monitoring Mission once in 3 years
- Review by World Bank, Global Fund, WHO and other stakeholders
- Guided by DGHS, Technical Advisory Committee and expert committees to take decisions on policies
- Regular interaction with WHO and other international organisations

Challenges to malaria control

- Challenges in Diagnosis
 - Sensitivity of RDTs
 - Turnaround time for microscopy reports
- Changing patterns of Malaria
- Challenges in Treatment
 - Artemisinin monotherapy (injectables used for uncomplicated malaria)
 - Drug resistance
 - Private sector treatment practices
- Challenges in Vector Control
 - Poor acceptance of indoor residual spray
- Lack of effective vaccine
- Access to healthcare delivery system
- Supply chain management

NVBDCP: Recent steps for malaria control

- Point of Care management: ASHAs
- Introduction of bivalent RDTs
- Evidence based policy changes
 - Drug Policy
 - Insecticide policy
- Banning oral artemisinin monotherapy (2009)
- Operational research
 - Monitoring antimalarial drug resistance
 - Monitoring insecticide resistance
 - Testing new products
 - Antimalarials
 - Diagnostics
 - Vector control tools
 - QA of medicines/diagnostics also undertaken by ICMR institutes

The way forward

- To bring down API to <1 by 2017 (as per 12th FYP) in all districts
- To halt and reverse the incidence of malaria by 2015 (MDG)

THANKS